EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Renal anemia: current treatments and emerging molecules

M Heras-Benito

Revista Clínica Española (English Edition) · 2023

DOI: 10.1016/j.rceng.2023.06.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Revista Clínica Española (English Edition), 2023. Verfasst von M Heras-Benito. Beteiligte Einrichtung: Nephrology Service, Hospital Universitario de Salamanca, Salamanca, Spain. Electronic address: mherasb@saludcastillayleon.es. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Anemia, Hematinics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anemia is a common complication of kidney disease and the prevalence increases as the disease progresses. It worsens the quality of life of patients and increases morbidity and mortality. The current rationale for treating renal anemia is based on the use of erythropoiesis-stimulating agents, iron supplementation and, to a lesser extent, the use of transfusions. Stimulation of endogenous erythropoietin synthesis and improvement of iron availability, through inhibition of prolil-hydroxilase-hypoxia-inducible factor (PH-HIF), represents a new oral alternative for renal anemia treatment. Clinical trials with PH-HIF inhibitors have demonstrated their efficacy in maintaining target hemoglobin levels. However, aspects concerning long-term safety are pending a clarification. In conclusion, advances in the pathogenesis of renal anemia make it possible to have current treatments to treat renal anemia. The development of new molecules, based on the inhibition of PH-HIF, represents a new effective alternative for anemia associated with kidney disease, especially in patients with resistance to erythropoiesis-stimulating agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicAnemiaHematinicsHumansQuality of LifeIronChronic Disease

Stichwörter der Autor:innen

Agentes estimuladores de eritropoyesisAnemiaChronic kidney diseaseEnfermedad renal crónicaEritropoyesisErythropoiesisErythropoiesis-stimulating agentsHypoxia-inducible factor prolyl-hydroxylase inhibitorsInhibidores de prolil-hidroxilasa de factor inducible por hipoxia

Substanzen

IronHematinics

Autor:innen und Institutionen

  • Nephrology Service, Hospital Universitario de Salamanca, Salamanca, Spain. Electronic address: mherasb@saludcastillayleon.es.

Zitieren

APA

Heras-Benito, M. (2023). Renal anemia: current treatments and emerging molecules. Revista Clínica Española (English Edition). https://doi.org/10.1016/j.rceng.2023.06.006

Vancouver

Heras-Benito M. Renal anemia: current treatments and emerging molecules. Revista Clínica Española (English Edition). 2023. doi:10.1016/j.rceng.2023.06.006

BibTeX
@article{HerasBenito2023,
  author = {Heras-Benito, M},
  title = {Renal anemia: current treatments and emerging molecules},
  journal = {Revista Clínica Española (English Edition)},
  year = {2023},
  doi = {10.1016/j.rceng.2023.06.006}
}
Kostenlos starten →